

Curriculum Vitae

1. Personal Data

Thomas S. Uldrick, M.D., M.S.

Place of Birth: Long Beach, CA

Work Contact:

Fred Hutchinson Cancer Research Center

1100 Fairview Ave. N., MI-B849

Mail stop MI -B 140

Seattle, WA 98109

P: 206-667-7485

F: 206-667-1965

E-mail: tuldrick@fredhutch.org

*Thomas S. Uldrick
June 4, 2019*

2. Education

May 1992

Bachelor of Arts

University of California, Berkeley, Berkeley, CA

1994 - 1997

Postbaccalaureate Premedical Program

Columbia University, School of General Studies, New York, NY

May 2002

Doctor of Medicine, summa cum laude

State University of New York Downstate Medical Center,
Brooklyn, NY

May 2008

Master of Science in Biostatistics, Patient Oriented Research
Track Columbia University, Mailman School of Public Health,
New York, NY

3. Post Graduate Training

June 2002 - June 2005

Resident, Internal Medicine

New York Presbyterian Hospital - Columbia University
Medical Center, New York, NY

July 2005 - June 2008

Postdoctoral Clinical Fellow, Hematology and Medical
Oncology New York Presbyterian Hospital - Columbia
University Medical Center, New York, NY

July 2008 - June 2009

Clinical Fellow, Hematology and Medical Oncology

HIV & AIDS Malignancy Branch, Center for Cancer Research,
National Cancer Institute, Bethesda, MD

4. Faculty. Positions Held

Date of Preparation of Curriculum Vitae June 4, 2019

July 2009 - sept 2015	Research, National Cancer Institute, Bethesda, MD
Sept 2015 - Nov 2017	Senior Clinician Clinical Director, HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
Nov 2017 - present	Deputy Head, Global Oncology Associate Member, Vaccine and Infectious Disease Division Associate Member, Clinical Research Division Fred Hutchinson Cancer Research Center, Seattle, WA
Dec 2017 - present	Staff Clinician HIV & AIDS Malignancy Branch, Center for Cancer
	Associate Professor of Medicine Division of Medical Oncology University of Washington, Seattle, WA

5. Hospital Positions Held

July 2008 - Nov 2017	Attending Physician National Institutes of Health Clinical Center, Bethesda, MD
Jan 2018 - present	Attending Physican UW Medicine, Seattle WA
Jan 2018 - present	Attending Physican Seattle Cancer Care Alliance, Seattle WA

6. Current Employment:

N/A

7. Honors

June 1999	Alumni Association Research Fellowship "Risk Factors for Rupture of Intracranial Aneurysms"
March 2001	Alpha Omega Alpha Elected during junior year
May 2002	Merck Manual Award Outstanding achievement in medical education
August 2007	American Society of Clinical Oncology/American Association of Cancer Research Workshop: Methods in Clinical Cancer Research, Full Scholarship, "Targeting Bcl-6 in the Treatment of Diffuse Large B-cell Lymphoma: A Translational Approach to Optimizing Vorinostat in Aggressive Lymphoma". Protocol open to accrual, NCT00691210

June 2006 - June 2008 Patient Oriented Research Scholar,
Full-Tuition Scholarship, Master of Science in Biostatistics

February 2009 Young Investigators Award, 16th Conference on Retroviruses and Opportunistic Infections, Full Conference Scholarship, " High-dose Zidovudine + Valganciclovir in the Treatment of Kaposi's Sarcoma-associated Herpesvirus-associated Multicentric Castleman's Disease: A Targeted Therapy Using Antiviral Drugs That Are Activated to Toxic Moeities by Kaposi's Sarcomaassociated Herpesvirus Lytic Genes"

2015 Cancer Therapy Evaluation Program Career Development LOI Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm

2016, 2017 CCR Federal Technology Transfer Award

8. Board Oualifications

August 2005 Board Certified, Internal Medicine
October 2008 Board Certified, Hematology
October 2008 Board Certified, Medical Oncology

9. Licensure

January 2004 New York State License, 230955
December 2017 Washington State License, MD6()803509

10. Professional Organizations

2005 — Present American Board of Internal Medicine
2008 — Present American Society of Clinical Oncology
2008 — Present American Society of Hematology

11. Teaching Responsibilities

2005 - 2007 Clinical Practice I Clerkship Supervisor
Columbia University College of Physicians and Surgeons
2008 - 2017 Clinical Supervisor
HIV and AIDS Malignancy Branch Clinic, Center for Cancer Research, NCI.
2017 Fellowship Program Director
HIV and AIDS Malignancy Research, Center for Cancer Research, NCI

A. Clinical Fellows / Faculty

- 2014 Manisha Bhutani, MD (Faculty, Levine Cancer Institute; Assistant Professor, University of North Carolina at Chapel Hill)
- 2013 -2017 Priscila Gongalves, MD (Associate Director for Novel Therapeutics, Northwell Health Cancer Institute)
- 2016-2017 Katheryn Lurain, MD MPH (Staff Clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research) 2017 Ramya Ramaswami, MBBS (Staff Clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research)
- 2017— Present Camille Puronen, MD (University of Washington Medical Oncology Fellow)
- 2018— Present Henry D'dungu, MD (Senior Fellow, Fred Hutchinson Cancer Institute)

B. Medical Students

- 2013 - 2016 David Fajgenbaum, MD, MBA (Assistant Professor, University of Pennsylvania)

C. Invited Lectures and Meetings

1. Update on Kaposi Sarcoma Herpes Virus (KSHV)-Associated Malignancies. Oncology Grand Rounds, Washington Hospital Center. Washington, DC. June 11, 2010.
2. Clinical Trial Status Update: Phase I and Pharmacokinetic Study of Sorafenib in patients with Kaposi Sarcoma. National Cancer Institute Cancer Therapy Evaluation Program Early Drug Development Meeting. Bethesda, MD. September 27, 2010.
3. Clinical Update: KSHV-associated Malignancies. NCI Medical Oncology Branch Lecture Series. Bethesda, MD. Dec 17, 2010.
4. KSHV-Associated Multicentric Castleman Disease and Associated Cytokine Disorders. NCI HIV and AIDS Malignancy Branch Seminar. Bethesda, MD. March 14, 2011.
5. KSHV-Associated Multicentric Castleman Disease and Associated Inflammatory Cytokine Disorders. NCI Medical Oncology Branch Lecture Series. Bethesda, MD. June 10, 2011.
6. Lymphoma in HIV Infected Patients. NIAID HIV Lecture Series. Bethesda, MD. June 21, 2011,
7. AIDS-related Lymphoma. American Society of Clinical Oncology University Tumor Board <http://universityofcalifornia.edu/education/continuing-education/2011-10-27-aids-related-lymphoma-asc-tumor-board>. October 27, 2011.
8. Anal Dysplasia and Malignancy: Prevalence, Diagnosis and Treatment with a focus on persons infected with HIV. DC Partnership for HIV/AIDS Progress; NIH, DOH/HAHSTA; Howard University College of Medicine, Office of CME. Washington, DC. November 1, 2011.

9. Update on Kaposi Sarcoma and Other Kaposi Sarcoma Herpesvirus (KSHV)Associated Malignancies. Oncology Grand Rounds, Washington Hospital Center. Washington, DC. April 13, 2012.
10. Advances in the Field of HIV-Related Malignancies. Centro de Cancer de la Montana Multidisciplinary Symposium: Translating the State of the Art Practice to Patient Care. Isla Verde, Puerto Rico. June 30, 2012.
11. Lymphoma and Lymphoproliferative Diseases in Patients with HIV; Clinical & Diagnostic Considerations and Treatment of Lymphoma & Lymphoproliferative Diseases in Patients with HIV; HAART, Chemotherapy and Rituximab. Pathpoint 2012 Congress. Cape Town, South Africa. September 29, 2012.
12. Expanding the Definition of Treatment as Prevention: Improving Cancer Related Outcomes in Patients with HIV. HealthHIV Treatment as Prevention Forum. Washington, DC. November 13, 2012.
13. Co-chair, Kaposi's Sarcoma-Associated Herpesvirus — Multicentric Castleman's Disease (KSHV-MCD) Meeting. Presentations: Virus-Activated Cytotoxic Drugs and other New Approaches in the Treatment of MCD and Response Criteria for Treatment Trials of KSHV-MCD, The Bethesda Criteria. Office of HIV and AIDS Malignancy (OHAM), NCI. Rockville, MD. March 12, 2013.
14. "When Anti-Retroviral Therapy is not Enough..."; HIV & Lung Cancer. Skeik V, Rosenberg A, Venkatesan AM, and Uldrick TS. NIH Clinical Center Clinicopathologic Grand Rounds. Bethesda, MD. May 22, 2013.
15. Oncology in Patients with HIV in the Era of Effective Antiretroviral Therapy. NCI Radiation Oncology Resident Lecture Series. Bethesda, MD. Jan. 22, 2014.
16. Hodgkin Lymphoma in Patients with HIV. NIAID Grand Rounds. Bethesda, MD. February 7, 2014.
17. Themed Discussion: Kaposi Sarcoma. Discussion Leader, Conference on Retroviruses and Opportunistic Infections 2014. Boston, MA. March 6, 2014.
18. Inflammation and Cancer in Patients with HIV: Challenges and Opportunities in Prevention and Treatment. Plenary Talk, Coinfection and Malignancies Subcommittee of the Inflammation Transformative Science Group Business Session; AIDS Clinical Trial Group Network Meeting. Washington, DC. June 25, 2014.
19. Evaluation of Advanced Kaposi Sarcoma and Targeted Therapy. NIH Clinical Center Dermatology Grand Rounds. Bethesda, MD. August 14, 2014.
20. Cancer in People with HIV: Challenges in the Era of Effective Antiretroviral Therapy. Center for Cancer Research Grand Rounds. Bethesda, MD. February 6, 2015.
21. Cancer in People with HIV in the Era of Contemporary Combination Antiretroviral Therapy: Challenges in Clinical Oncology Research. Office of

- Hematology & Oncology Products, CDER, FDA. Silver Spring, MD. April 6, 2015.
22. Clinical Advances in Kaposi Sarcoma Herpesvirus Associated Malignancies. Johns Hopkins University. Bethesda, MD. April 7, 2015.
 23. Diagnosis and Detection of other KSHV-associated Disease in Sub-Saharan Africa. AIDS Malignancy Consortium sponsored symposium: Confronting the Challenges Relevant to HIV/AIDS Malignancies in Sub-Saharan Africa. Cape Town, South Africa. August 1, 2015.
 24. Cancer in people with HIV in the era of contemporary antiretroviral therapy: challenges and opportunities for improving clinical trial inclusion criteria. Symposium; Office of Hematology & Oncology Products; in collaboration with Division of Antiviral Products and Office of Clinical Pharmacology; FDA. Silver Spring, MD. August 17, 2015.
 25. International Symposium on Idiopathic Multicentric Castleman Disease. Participant, Diagnostic Criteria Workshop. Castleman Disease Collaborative Network and the Orphan Disease Center of the University of Pennsylvania, Philadelphia, PA. November 21-22, 2015.
 26. Cancer in People with HIV: Challenges in the Era of Effective Antiretroviral Therapy. MedStar Washington Hospital Center Department of Medicine Grand Rounds. Washington, DC. December 2, 2015.
 27. Development of Consensus iMCD Criteria: Summary of the 2015 International Castleman Disease Diagnostic Criteria Meeting. Accelerating Research & Treatment for Castleman Disease. Orlando, FL. December 5, 2015.
 28. Early ART, What Improves and What Does Not: Lessons from START. EndOrgan Disease/Inflammation Scientific Session, AIDS Clinical Trials Group Scientific Retreat. Boston, MA. February 26, 2016.
 29. HIV Medications: Carcinogenicity and Chemoprevention. HIV and Cancer Workshop. Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI. Bethesda, MD. April 6, 2016.
 30. HIV Working Group Draft Recommendations. American Society of Clinical Oncology and Friends of Cancer Research Modernizing Eligibility Criteria Project. Alexandria, VA. May 12, 2016.
 31. KSHV-associated B-cell Tumors: Multicentric Castleman Disease and Primary Effusion Lymphoma. NIH Clinical Center Rounds. Bethesda, MD. May 25, 2016.
 32. Cancer in People with HIV in the ART era. Columbia University Division of Infectious Disease Morning Conference. New York, NY, May 26, 2016.
 33. Pathologic Immune Responses to co-Infections in HIV: Two Rare Diseases, One Therapeutic Target. Manion M, Hammoud D, Pittaluga S, [Jldrick TS](#), and Sereti I. NIH Clinical Center Rounds. Bethesda, MD. June 1, 2016,

34. Kaposi Sarcoma and the Challenge of HIV Antiretroviral Treatment Failure. Lacsina J, Pau A, and UldricKTS. NIAID Grand Rounds. Bethesda, MD. December 12, 2016.
35. Advances in Kaposi Sarcoma Herpesvirus-associated Malignancies. George Washington University Oncology Grand Rounds. Washington, DC. January 27, 2017.
36. Immune Dysregulation in KSHV-associated Malignancies: Redefining the Spectrum of Disease and Novel Immune Modulatory Therapies. Fred Hutchinson Cancer Research Center. Seattle, WA. March 13, 2017.
37. Modernizing Eligibility Criteria: Inclusion of Patients with HIV in Cancer Clinical Trials. 2017 Accelerating Anticancer Agent Development and Validation Research. Bethesda, MD. May 4, 2017.
38. Progress Update on CITN-12: Pembrolizumab in Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms. Delaney AIDS Research Annual Meeting. San Francisco, CA. June 23, 2017.
39. Clinical Trial Design Considerations: Leveraging Cancer Immunotherapy Studies to Evaluate HIV Endpoints. International AIDS Society HIV Cure & Cancer Forum, Marie Curie Institute. Paris, France. July 23, 2017.
40. KSHV-Associated Diseases in the ART Era. 2nd Annual Malawi Cancer Symposium. Lilongwe, Malawi. August 28, 2017.
41. Gene Therapy and Stem Cell Transplant, Moderator, 16th International Conference on Malignancies in HIV/AIDS 2017; Bethesda, MD. October 20, 2017.
42. Interim Safety Analysis of Cancer Immunotherapy Trials Network-12: A Phase 1 Study of Pembrolizumab in Patients with HIV and Relapsed, Refractory or Disseminated Malignancies. HIV Persistence During Therapy: 8th International & Eradication Strategies Workshop. Miami, FL. December 12, 2017.
43. Prevention of Cancer in People with HIV. National Cancer Prevention Day. Washington, DC. February, 7, 2018.
44. Safety of Pembrolizumab in People Living with HIV: Interim CITN12 experience. 2018 Annual AIDS Clinical Trial Group Retreat, Cure Transformative Science Group Session. Boston, MA. March 8, 2018
45. Immunotherapy for KSHV-associated and HIV-associated Malignancies. American Association for Cancer Research Education Session: New Insights into the Biology and Treatment of Virus-Associated Malignancies. Chicago, IL. April 14-18, 2018.
46. Pembrolizumab in people with HIV and Cancer: Interim CITN12 experience. Division of AIDS Workshop on Development of Monoclonal Antibodies to Achieve a Drug-free Sustained Virologic Remission for HIV. Rockville, MD. June 13, 2018.
47. Immunotherapy for KSHV-associated (and HIV-associated) Malignancies. 2018 Fred Hutchinson Cancer Research Center Vaccine and Infectious Disease Division Retreat. Union Washington. June 26, 2018.

48. Biology and Management of HIV-associated Lymphomas, Malignancies in People with HIV Symposium. IDWeek 2018. San Francisco, CA. October 6, 2018.
49. Broadening Eligibility Criteria to Make Clinical Trials More Representative: Joint Project of the American Society of Clinical Oncology and Friends of Cancer Research. Presentation to the Executive Committee. ECOG-ACRIN 2018 Group Meeting. Ft. Lauderdale, FL. October 25, 2018.
50. Interleukin-7 and HIV: Rationale for IL-7 in Kaposi Sarcoma and Other HIV-associated Cancers. Kyung Hee and Genexine Cancer Symposium. Seoul, Korea. December 14, 2018
51. Advances in KSHV-Associated Malignancies. Institute of Infectious Disease and Molecular Medicine. University of Cape Town. April 9, 2019.

12. Editorial Responsibilities

N/A

13. Special National Responsibilities

- | | |
|------|--|
| 2010 | Primary Central Nervous System Lymphoma Working Group
NCI Lymphoma Steering Committee |
| 2011 | - present Independent Endpoint Review Committee, Trials
A5263/A5264 AIDS Clinical Trials Group |
| 2013 | — present Scientific Advisory Board
Castleman Disease Collaborative Network |
| 2014 | 2018 End-organ Disease and Inflammation Transformative Science
Group, including Co-Infections and Malignancies (COIMAL)
Subcommittee
AIDS Clinical Trials Group |
| 2016 | - present Eligibility Criteria Project, HIV Working Group, Chair American
Society of Clinical Oncology — Friends of Cancer Research |
| 2016 | — present Oncologic Drugs Advisory Committee US Food and
Drug Administration |
| 2017 | Program Committee
16 th International Conference on Malignancies in HIV/AIDS |
| 2018 | Scientific Advisory Board
2018 International Conference on EBV and KSHV |
| 2018 | — present Adult Steering Committee
Cancer Immunotherapies Trials Network |

- 2019 Planning Committee
17th International Conference on Malignancies in HIV/AIDS
- 2019 Clinical Working Group Member
NIH HIV-associated Comorbidities Workshop

14. Special Local Responsibilities

- 2005 - 2008 Residency Recruitment Selection Committee
Department of Medicine, Columbia University
- 2009 - 2017 Medical Oncology Fellowship Committee
Medical Oncology Branch, Center for Cancer Research, NCI
- 2008 - 2017 Medical Oncology Branch Scientific Review Committee
Center for Cancer Research, NCI
- 2010 - 2013 Safety Monitoring Committee, Reviewer Center
for Cancer Research, NCI
- 2013 - 2017 Safety Monitoring Committee, Chair Center
for Cancer Research, NCI
- 2018 — present Epidemiology Faculty Recruitment Committee Fred
Hutchinson Cancer Research Center

Research Funding

A. Grants and Loan Repayment

- 2006 - 2008 Grant Number ULI RR024156, National Center for
Research
Resources (NCRR)
Patient Oriented Research Scholar
Columbia University's Clinical and Translational Science Award
PI Henry Ginsberg, MD
- 2007 - 2008 Grant Number 2R25CA094061-06
Postdoctoral Fellow
Training Program in Cancer-Related Population Sciences
The Mailman School of Public Health PI
Alfred I Neugut, MD, PhD
- 2008 Grant Number 5D43TW000231-13, Fogarty International Center
Postdoctoral Trainee
International Training Program in Epidemiology of AIDS The
Columbia University-Southern African Fogarty AIDS International
Training and Research Program (AITRP)
PI Quarraisha Abdool Karim, PhD

2008 - 2014	P.L. 100-607, Section 487A (42 USC 288-1) NIH AIDS Research Loan Repayment Program
2015 - 2017	ZIA BC 011700, Patient Oriented Research in Viral Malignancies and HIV-associated Cancers FY2016: \$1,114,919
2018 — present	Grant Number ROI CA206466-02, National Cancer Institute (co-PIs Frenkel and Casper) HIV Integration-Mediated Modulation of Immune Regulation in HPV-Associated Cancers Fred Hutchinson Cancer Center Principal Investigator
2018 — present	Grant Number 3P30CA015704-43S2, National Cancer Institute. Evaluation of the effects of HIV on accumulation of somatic mutations in lung cancer associated genes
 B. Protocols	
2008 - 2017	Associate Investigator Center for Cancer Research, NCI Protocol 01-C-0038 Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Virus-related Premalignant Lesions, and/or Cancer PI Robert Yarchoan
2008 - 2017	Associate Investigator Center for Cancer Research, NCI Protocol 01-C-()158 Protocol to access vascularity in Kaposi 's sarcoma lesions utilizing non-invasive imaging techniques PI Robert Yarchoan
2008 - 2013	Associate Investigator Center for Cancer Research, NCI Protocol 01 -C-OI 93 A study of the effects of potent anti-HIV therapy on parameters hypothesized to be related to the pathogenesis of Kaposi's sarcoma (KS) in HIV-infected individuals PI Robert Yarchoan
2008 - 2011	Center for Cancer Research, NCI 03-C-OI 10 Phase II study of intravenous recombinant humanized anti-vascular endothelial cell growth factor antibody (bevacizumab) in classical (HIV-negative) and in AIDS-associated Kaposi's sarcoma PI Robert Yarchoan
2008 - 2017	Associate Investigator Center for Cancer Research, NCI 04-C-0275 Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease with Laboratory and Clinical Correlates of Disease Activity PI Robert Yarchoan

2008 - 2017 Associate Investigator
Center for Cancer Research, NCI Protocol 06-C-0051
AIDS-related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate with Leucovorin Rescue and Highly Active Antiretroviral Therapy
PI Robert Yarchoan

2008 - 2017 Associate Investigator
Center for Cancer Research, NCI Protocol 06-C-0083
Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in patients with Kaposi's sarcoma PI Robert Yarchoan

2009 - 2017 Lead Associate Investigator
Center for Cancer Research, NCI Protocol 09-C-0130
Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab Followed by Bevacizumab Monotherapy in Adults with Advanced Kaposi's Sarcoma
PI Robert Yarchoan

2011 - 2017 Lead Associate Investigator
Center for Cancer Research, NCI Protocol 11-C-0129
A Pilot Trial Assessing the Feasibility of Delivering Topical MTS01 to Reduce Dermatitis in Patients Receiving Intensity Modulated radiation with Concurrent 5-Fluoruracil and Mitomycin-C for Stage 1-111 Carcinoma of the Anal Canal
PI Deborah Citrin

2011 - 2017 Associate Investigator
Center for Cancer Research, NCI Protocol 11-C-0220
Natural History of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies
PI Robert Yarchoan

2011 - 2017 Principal Investigator
Center for Cancer Research, NCI Protocol 11-C-0233
Pilot Study of Tocilizumab in Patients with Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)- associated Multicentric Castleman Disease

2011 - 2017 Associate Investigator
Center for Cancer Research, NCI Protocol 12-C-0047
Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals with or without HIV
PI Robert Yarchoan

- 2016 — present Principal Investigator
Cancer Immunotherapy Trials Network 12 (Multicenter Study)
Phase I Study of Pembrolizumab in Patients with Human
Immunodeficiency Virus (HIV) and Relapsed/Refractory or
Disseminated Malignant Neoplasm
- 2016— present Associate Investigator (Principal Investigator 2016-2017)
Center for Cancer Research, NCI Protocol 16-C-0047
A Phase 1 Trial of Pomalidomide in Combination with Liposomal
Doxorubicin in Patients with Advanced or Refractory Kaposi
Sarcoma
- 2016— present Associate Investigator (Principal Investigator 2016-2017)
Center for Cancer Research, NCI Protocol 16-C-OI 71
Phase 1/11 Study of Lenalidomide Combined with Modified
DAEPOCH and Rituximab (EPOCH-R²) in Primary Effusion
Lymphoma or KSHV-Associated Large Cell Lymphoma
- 2017 Lead Associate Investigator
Molecular Characterization of Viral-associated Tumors, Tumors
Occurring in the Setting of HIV or Other Immune Disorders and
Castleman Disease
- 2018 — Present Principal Investigator
Fred Hutchinson Cancer Research Center Protocol U028 IR
File 10040
A Phase I Study of Subcutaneous Rituximab Hyaluronidase
Combined with Local Standard-of-Care Chemotherapy for the
Treatment of Burkitt Lymphoma, Diffuse Large B-Cell
Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus
Associated Multicentric Castleman Disease in Pediatrics and
Adults in Uganda

16. Bibliography

A. Publications in Refereed Journals

1. Hirano M, Marti R, Casali C, Tadesse S, Uldrick T, Fine B, Escolar DM, Valentino ML, Nishino I, Hesdorffer C, Schwartz J, Hawks RG, Martone DL, Cairo MS, DiMauro S, Stanzani M, Garvin JH Jr, Savage DG. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. *Neurology*. 2006 Oct 24;67(8): 1458-60. PMID 16971696. [original work]
2. Mosam A, Carrara H, Shaik F, Uldrick T, Berkman A, Aboobaker J, Coovadia HM. Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983-2006). *Int JSTD AIDS*. 2009 Aug;20(8):553-6. PMID 19625587. [original work]
3. * Uldrick TS, Wang V, O'Mahony D, Aleman K, Wyvill KM, Marshall V, Steinberg SM, Pittaluga S, Maric I, Whitby D, Tosato G, Little RE, Yarchoan R. An IL-6-related systemic

- inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without multicentric Castleman disease. *Clin Infect Dis*. 2010 Aug 3;350-8.PMID 20583924. [original work]
4. Abend JR, Uldrick TS, Ziegelbauer JM. Regulation of tumor necrosis factor-like weak inducer of apoptosis receptor protein (TWEAKR) expression by Kaposi's sarcoma-associated herpesvirus microRNA prevents TWEAK-induced apoptosis and inflammatory cytokine expression. *J Virol*, 2010 Dec;84(23):12139-51. PMID 20844036. [original work]
 5. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA. Cancer Burden in the HIV-Infected Population in the United States. *J Natl Cancer Inst*. 2011 May 4;103(9):753-62. PMID 21483021. [original work]
 6. * Uldrick TS, Polizzotto MN, O'Mahony D, Aleman K, Wyvill KM, Wang V, Marshall V, Pittaluga S, Steinberg SM, Tosato G, Whitby D, Little RF, Yarchoan R. High-dose zidovudine in combination with valganciclovir in the treatment of symptomatic Kaposi sarcoma-associated herpesvirus-associated multicentric Castleman disease: A pilot study of virus-activated cytotoxic therapy. *Blood* 2011 Jun 30; 117(26):6977-86. PMID 21487108. [original work]
 7. Kang JG, Majerciak V, Uldrick TS, Wang X, Kruhlak M, Yarchoan R, Zheng Z. Kaposi sarcoma-associated herpesviral IL6 and human IL6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation. *J Pathol*, 2011 Nov;225(3):378-89.PMID 21984125. [original work]
 8. Mosam A, Uldrick TS, Shaik F, Carrara H, Aboobaker J, Coovadia HM. An evaluation of the early effects of a combination antiretroviral therapy programme on the management of AIDS-associated Kaposi's sarcoma in KwaZulu-Natal, South Africa. *Int J STD AIDS*. 2011 Nov;22(11):671-3. PMID 22096054. [original work]
 9. Gasperini P, Espigo I-Frigole G, Salvucci O, Maric D, Uldrick TS, Polizzotto MN, Yarchoan R, Tosato G. Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling. *Cancer Res*. 2012 Mar ;1157-69.PMID 22237624. [original work]
 10. Polizzotto MN, Uldrick TS, Hu D, and Yarchoan R. Clinical Manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. *Front Microbiol*. 2012 Mar 2;3:73. PMID 22403576. [original work]
 11. Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, and Yarchoan R. A Phase II Study of Bevacizumab in Patients with Human Immunodeficiency Virus-associated Kaposi Sarcoma on Antiretroviral Therapy. *J Clin Oncol*. 2012 May ;1476-83.PMID 22430271. [original work]

12. Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, and Coovadia HM. A randomized controlled trial of HAART versus HAART and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. *J Acquir Immune Defic Syndr*. 2012 Jun 1;60(2):150-157. PMID 22395672. [original work]
13. Ray A, Marshall V, Uldrick T, Leighty R, Labo N, Wyvill K, Aleman K, Polizzotto MN, Little RF, Yarchoan R, and Whitby D. Sequence Analysis of KSHV microRNAs in patients with Multicentric Castleman Disease and KSHV-associated Inflammatory Cytokine Syndrome. *J Infect Dis*. 2012 Jun;205(11):1665-76. PMID 22448005. [original work]
14. Abend JR, Ramalingam D, Kieffer-Kwon P, Uldrick TS, Yarchoan R, and Ziegelbauer JM. KSHV microRNAs target two components of the TLR/IL-IR signaling cascade, IRAKI and MYD88, to reduce inflammatory cytokine expression. *J Virol*. 2012 Nov;82(21):1163-74. PMID 22896623. [original work]
15. Sakakibara S, Espigol-Frigole G, Gasperini P, Uldrick TS, Yarchoan R, and Tosato G. A20/TNFAIP3 inhibits NF-KB activation induced by the Kaposi's sarcoma-associated herpesvirus vFLIP oncoprotein. *Oncogene*. 2013 Mar 7;32(10):1223-32. PMID 22525270. [original work]
16. Venkataraman G, Uldrick TS, Aleman K, O'Mahony D, Karcher DS, Steinberg SM, Raffeld MA, Marshall V, Whitby D, Little RF, Yarchoan R, Pittaluga S, and Maric I. Bone marrow findings in HIV positive patients with Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. *Am J Clin Pathol*. 2013 May; 139(5):65. PMID 23596117. [original work]
17. Dong HY, Wang W, Uldrick TS, Gang M. HHV8 and EBV-associated solitary B cell Lymphoma with a T Cell Immunophenotype. *Leuk Lymphoma*. 2013 Jul;54(7): 1560-3. PMID 23228024. [original work]
18. De Witt P, Maartens DJ, Uldrick TS and Sissolak G. Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting of roll-out of combination antiretroviral therapy in South Africa. *J Acquir Immune Defic Syndr*. 2013 Sep 1;66-73. PMID 23797692. [original work]
19. Polizzotto MN, Uldrick TS, Wang V, Aleman K, Wyvill KM, Marshall V, Pittaluga S, O'Mahony D, Whitby D, Tosato G, Steinberg SM, Little RF, and Yarchoan Y. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. *Blood*. 2013 Dec 19;122(26):4189-98. PMID 24174627. [original work]
20. Kainerstorfer JM, Polizzotto MN, Uldrick TS, Rahman R, Hassan M, Najafizadeh L, Ardeshipour Y, Wyvill KM, Aleman K, Smith PD, Yarchoan R, Gandjbakhche AH. Evaluation of non-invasive multispectral imaging as a tool for measuring the effect of systemic therapy in Kaposi sarcoma. *PLOS One*, 2013 Dec 27;8(12):e83887. PMID 24386302. [original work]

21. Uldrick TS, Pipkin S, Scheer S, and Hessol NA. Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma. *AIDS*, 2014 Jan ;397-401.PMID 24076659. [original work]
22. Shahbazi S, Peer CJ, Polizzotto MN, Uldrick TS, Roth J, Wyvill KM, Aleman K, Zeldis JB, Yarchoan R, and Figg WD. A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. *J Pharm BiomedAna1*. 2014 Apr ;5;92:63-8. PMID 24486861. [original work]
23. Labo N, Miley W, Marshall V, Gillette W, Esposito D, Bess M, Turano A, Uldrick T, Polizzotto MN, Wyvill KM, Bagni R, Yarchoan R, and Whitby D. Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systemic analysis of the KSHV proteome. *Plos Pathog* 2014 Mar 27; 0(3):e1004046. PMID 24675986. [original work]
24. * Uldrick TS, Polizzotto MN, Aleman K, Wyvill KM, Marshall V, Whitby D, Wang V, Pittaluga S, O'Mahony D, Steinberg SM, Little RF, and Yarchoan R. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. *Blood*, 2014 Dec 4; 24(24):3522-52. PMID 25331113. [original work]
25. Kranick SM, Stetler-Stevenson M, Aleman A, Polizzotto MN, Little RF, Yarchoan R and Uldrick TS. Paradoxical Central Nervous System Immune Reconstitution Syndrome in Acquired Immunodeficiency-related Primary Central Nervous System Lymphoma. *Haematologica*. 2015 Jan; 100:e21-e24. PMID 25304612. [original work]
Uldrick TS and Little RF. How we treat classical Hodgkin lymphoma in patients with HIV. *Blood*. 2015 Feb 19;125(8):1226-35. PMID 25499453. [review]
27. Polizzotto MN, C, Uldrick TS, Alen Millo Aleman K, Whatley M, Wyvill KM, O'Mahony D, Whitby D, Maass-Moreno R, Steinberg SM, Little RF, and Yarchoan, R. ¹⁸F-DG PET in KSHV-associated multicentric Castleman disease: correlation with activity, severity, inflammatory and virologic parameters. *J Infect Dis*. 2015 Oct 1250-60. PMID 25828248. [original work]
28. Kieffer-Kwon P, Happel C, Uldrick TS, Ramalingam D, Ziegelbauer JM. KSHV MicroRNA Repress Tropomyosin 1 and Increase Anchorage-Independent Growth and Endothelial Tube Formation. *PLOS one*. 2015 Aug 11;10(8):e0135560. PMID 26263384. [original work]
29. Hu DS, Wang V, Yang M, Abdullh S, Davis DA, Uldrick TS, Polizzotto MN, Veeranna R, Pittaluga S, Tosato G, and Yarchoan R. Induction of Kaposi Sarcoma Herpesvirus-encoded Viral Interleukin-6 by X-Box Binding Protein-I. *J Virol*. 2015 Oct 21;90(1):368-78. PMID 26491160. [original work]
30. Simonetti FR, Sobolewski MD, Fyne E, Shao W, Spindler J, Hattori J, Anderson EM, Watters SA, Hill S, wu X, Wells D, su L, Luke B, Halves EK, Besson G, Penrose KJ, Yang Z, Kwan RW, Van Waes C, Uldrick T, Citrin D, Kovacs J, Polis M, Rehm C, Gorelick R, Piatak J, Keele B, Kearney ME, Coffin JM, Hughes SH, Mellors JW,

- Maldarelli F. Clonally Expanded CD4+ T-cells Can Produce Infectious HIV-I in vivo. PMS. 2016 Feb 16;113(7):1883-8. PMID 26858442. [original work]
31. Polizzotto MN, Uldrick TS, wyvill KM, Aleman K, Marshall V, wang V, Whitby D, Pittaluga S, Jaffe E, Millo C, Tosato G, Little RF, Steinberg SM, Sereti I, and Yarchoan R. Clinical features and outcomes of patients with symptomatic KSHV-associated inflammation: prospective characterization of the Kaposi sarcoma herpesvirus inflammatory cytokine syndrome (KICS). Clin InfDis. 2016 Mar 15;62(6):730-8. PMID 26658701. [original work]
 32. Pratt D and Uldrick TS. Primary effusion lymphoma and progressive Kaposi sarcoma in the setting of elevated interleukin-6. Blood. 2016 Jun; 27(23):2940. PMID 28092896. [case report]
 33. Sissolak G, Seftel M, Uldrick TS, Esterhuizen TM, Mohamed N, Kotze D Burkitt lymphoma and B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in patients with HIV: Outcomes in a South African public hospital. J Global Oncol. 2016 Aug12(8):e0182750. PMID 28717763. [original work]
 34. Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Bevans M, Sereti I, Maldarelli F, Whitby D, Marshall V, Gongalves PH, Khetani V, Figg WD, Steinberg SM, Zeldis JB, Yarchoan R. Pomalidomide for Symptomatic Kaposi Sarcoma in People with and without HIV Infection: A Phase 1/11 study. J Clin Oncol. 2016 Dec;34(34):3131. PMID 27863194. [original work]
 35. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong, RSM, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglia M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fossa A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, ElenitobaJohnson KS.J, and Lim MS. International, Evidence-based Consensus Diagnostic Criteria for HHV-8-negative/idiopathic Multicentric Castleman Disease. Blood. 2017 Mar; 29(12):1646-57. PMID 28087540. [original work]
 36. Yu L, Tu M, Cortes J, Xu-Monette zy, Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu pc, Akosile MA, Uldrick TS, Yarchoan Y, Medeiros LJ, li Y, Fajgenbaum DC, Young KH. Clinical and Pathological Characteristics of HIV- and I-IHV8- negative Castleman Disease with Dysregulated Heterogeneous Profile. Blood. 2017 Mar;129(12):1658-1668. PMID 28100459. [original work]
 37. Musich T, Jones JC, Keele BF, Miller-Jenkins LM, Demberg T, Uldrick TS, Yarchoan R, and Robert-GuroffM. Flow virometric sorting of infectious HIV quasispecies from plasma for genomic and proteomic analysis. JCI Insight, 2017 Feb 23;2(4):e90626. PMID 28239654. [original work]
 38. Uldrick TS Gongalves PH, Wyvil KM, Peer CJ, Bernstein W, Aleman K, Polizzotto MN, Venzon D, Steinberg SM, Marshall V, Whitby D, Little RF, Wright JJ, Rudex MA, Figg

- WD and Yarchoan R. A Phase I Study of Sorafenib (BAY-43-9006) in Patients with Kaposi Sarcoma. *The Oncologist*. 2017, May;22(5):505-e49. PMID 28341759. [original work]
39. Sanchez-Martin D, Uldrick TS, Kwak H, Ohnuki H, Polizzotto MN, Annunziata CM, Raffeld M, Wyvill KM, Wang V, Marshall VA, Whitby D, Yarchoan R, and Tosato G. Evidence for a Mesothelial Origin of Body Cavity Lymphomas. *J Natl Cancer Inst*. 2017 Sept 1; 109(9). PMID 28376153. [original work]
 40. Royse RE, El Chaer F, Amirian ES, Hartman C, Krown SES Uldrick TS, Lee JY, Shepard Z, Chiao E Y. Disparities in Kaposi sarcoma incidence and survival in the United States: 2000-2013. *PLoS One*. 2017 Aug 22; 82750. PMID 28829790. [original work]
 41. Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, UldrickTS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Mayer E, Rubin E, Multani P, Prowell TM, Schenkel C, Kozak M, Allen J, Sigal E, Schilsky RL. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. *J Clin Oncol*. 2017 Nov 20;35(33):3737-3744. PMID 28968170. [original work]
 42. Uldrick TS, Ison G, Rudek MA, Noy A, Schwartz K, Bruinooge S, Schenkel C, Miller B, Dunleavy K, Wang J, Zeldis J, Little RE Modernizing Eligibility Criteria Project: Recommendations from the American Society of Clinical Oncology and Friends of Cancer Research HIV Working Group. *J Clin Oncol*. 2017 Nov 20;35(33):3774-3780. PMID 28968173. [original work]
 43. Roshan R, Labo N, Trivett M, Milcy W, Marshall V, Coren L, Cornejo Castro EM, Perez H, Holdridge B, Davis E, Matus-Nicodemo R, Ayala VI, Sowder R, Wyvill KM, Aleman K, Fennessey C, Lifson J, Polizzotto, MN, Douek D, Keele B, UldrickTS, Yarchoan R, Ohlen C, Ott D, and Whitby D. T-Cell Responses to KSHV Infection: A Systematic Approach. *Oncotarget*, 2017 Nov 25;8(65): 109402-109416. PMID 29312617. [original work]
 44. Shaik F, Uldrick TS, Esterhuizen T, Mosam A. Health related quality of life in patients treated with antiretroviral therapy only versus chemotherapy and antiretroviral therapy for HIV-associated Kaposi sarcoma: a randomized control trial. *J Global Oncol*. 2018 Oct; (4):1-9. PMID 30354935. [original work]
 45. Manion M, Uldrick TS Polizzotto MN, Sheikh V, Roby G, Lurain K, Metzger D, Mican J, Pau P, Lisco A, Laidlaw E, Hammoud D, Yarchoan R and Sereti I. Emergence of Kaposi sarcoma herpes virus complications following corticosteroid use in TB-IRIS. *Open Forum Infect Dis*. 2018 Oct;5(10):ofy217. PMID 30568973. [original work]
 46. Marshall VA, Labo N, Sztuba-Solinska J, Cornejo-Castro EM, Aleman K, Wyvill KM, McNamara L, Le Grice SF, Yarchoan R, UldrickTS, MacPhail P, Polizzotto MP, and Whitby D. Polymorphisms in KSHV-encoded microRNA sequences affect levels of mature viral microRNA in Kaposi Sarcoma lesions. *Oncotarget*, 2018 Nov;9(88):3585635869. PMID 30533200. [original work]

47. Tagawa T, Gao S, Koparde VN, Gonzalez M, Spouge JL, Serquifia AP, Lurain K, Ramaswami R, Uldrick TS, Yarchoan R, and Ziegelbauer JM. Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA. *Proc Natl Acad Sci*, 2018 Dec; 15(50):12805-12810. PMID 30455306. [original work]
48. Pastrana DV, Peretti A, Welch NL, Borgogna C, Olivero C, Badolato R, Notarangelo LD, Gariglio M, FitzGerald PC, McIntosh CE, Reeves J, Starrett GJ, Bliskovsky V, Velez D, Brownell I, Yarchoan R, Wyvill KM, Uldrick TS, Maldarelli F, Lisco A, Sereti I, Gonzalez CM, Androphy EJ, McBride AA, Van Doorslaer K, Garcia F, Dvoretzky I, Liu JS, Han J, Murphy PM, McDermott DH, Buck CB. Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency. *mSphere*. 2018 ;3(6).pii:e00645-18. PMID 30541782. [original work]
49. van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Schilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS Casper C, Oksenhendler E, Fajgenbaum DC. *Blood*.2018 Nov 15;132(20):2115-2124. PMID 30181172. [original work]
50. Lurain K, Polizzotto MN, Aleman K, Bhutani M, Wyvill KM, Goncalves PH, Ramaswami R, Marshall VA, Miley W, Steinberg SM, Little RF, Wilson W, Filie AC, Pittaluga S, Jaffe ES, Whitby D, Yarchoan R and Uldrick TS. Viral, Immunologic, and Clinical Features of Primary Effusion Lymphoma. *Blood*. 2019 April 18;133(16): 17531761. PMID 30782610. [original work]
51. Ramaswami R* , Uldrick TS*, Polizzotto MN, Wyvill KM, Gongalves P, Widell A, Lurain K, Steinberg SM, Figg WD, Tosato G, Whitby D, and Yarchoan R. A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. *Clin Cancer Res*. 2019 April 12 [Epub ahead of print]. PMID 30979736. [original work]
52. Blumenthal MJ, Schutz C, Barr D, Locketz M, Marshall V, Whitby D, Katz AA, Uldrick TSS Meintjes G; and Schäfer G. The contribution of KSHV to mortality in hospitalized HIV-infected patients being investigated for tuberculosis in South Africa. *J Infect Dis*. 2019 April 20 [Epub ahead of print]. PMID 31004430. [original work]
53. McGoldrick SM, Mutyaba I , Adams SV, Larsen A, Krantz EM, Namirembe C, Mooka P, Nabakooza S, Ndagire M, Mubiru K, Nabwana M, Nankinga R, Gerds S, Gordon-Maclean C, Geriga F, Omoding A, Sessle E, Kambugu J, Uldrick TS, Orem J, Casper C. Survival of children with endemic Burkitt Lymphoma in a prospective clinical care project in Uganda. *Pediatr Blood Cancer*. 2019 June 3:e27813[Epub ahead of print] [original work]
54. Uldrick TS, Gongalves PH, Abdul-Hay M, Claeys AJ, Emu B, ErnstoffMS, Fling SP, Fong L, Kaiser JC, Kohrt HE, Lacroix AM, Lee SY, Lundgren LM, Lurain K, Parsons

CH, Peeramsetti S, Ramaswami R, Sharon E, Sznol M, Wang CJ, Yarchoan R, and Cheever MA. Phase 1 Study of Pembrolizumab in Patients with HIV and Advanced Cancer. JAMA Oncol. 2019 June 2 [Epub ahead of print] [original work]

B. Book Chapters

1. Neugut A and Uldrick T. Chapt. 26: Second Malignancies After Chemotherapy. In: Perry MC (Ed). The Chemotherapy Source Book, Fourth Edition. University of Missouri, Columbia: Lippincott Williams & Wilkins (LWW); 2008:259-272.
2. Reingold SR, Neugut AI, Uldrick T, and Meadows AT. Chapt. 135: Treatment-Related Secondary Cancers. In: Hong, Bast, Hait, Kufe, Pollack, Weichselbaum, Holland, Frei (Eds.) Cancer Medicine 8. B.C. Deckert Inc; 2009,
3. Yarchoan R, Uldrick TS, Little R. Immunosuppression-Related Malignancies: Acquired Immunodeficiency Syndrome-Related Malignancies. In: DeVita VT, Lawrence S, Rosenberg SA (Eds.). Cancer: Principles & Practice Q/ Oncology, 9th Ed. Philadelphia, PA: Lippincott Williams & Wilkins (LWW); 201 1:2247-2262.
4. Uldrick TS, Polizzotto M, Yarchoan R. HIV-Associated Malignancies. In: Skeel, Roland. (Eds.). Handbook of Cancer Chemotherapy, 8th Ed, Philadelphia, PA: Lippincott Williams & Wilkins (LWW)•,2011:523-543;1915.
5. Becker D, Uldrick TS- and Neugut AI. Chapt. 24: Second Malignancies After Chemotherapy. In: Perry MC (Ed). The Chemotherapy Source Book, Fifth Edition. University of Missouri, Columbia: Lippincott Williams & Wilkins (LWW); 2012:289308.
6. Yarchoan R, Uldrick TS, Polizzotto MN. HIV-Associated Cancers. In: Yarchoan (Ed.). Cancers in People with HIV and AIDS. New York, NY: Springer; 2014:3-16.
7. Davidson-Moncada J, Uldrick TS. AIDS-related Primary Central Nervous System Lymphoma. In: Yarchoan (Ed.). Cancers in People with HIV and AIDS. New York, NY: Springer; 2014:207-222.
8. Polizzotto MN, Uldrick TS, and Yarchoan R. Multicentric Castleman Disease. In: Yarchoan (Ed.). Cancers in People with HIV and AIDS. New York, NY: Springer; 2014:245-262.
9. Yarchoan R, Uldrick TS, Polizzotto MN, Little RF. Immunosuppression-Related Malignancies: Acquired Immunodeficiency Syndrome-Related Malignancies. In: DeVita VT, Lawrence S, Rosenberg SA (Eds.). Cancer: Principles & Practice of Oncology, 10th Ed. Philadelphia, PA: Lippincott Williams & Wilkins (LWW); 2015: 1780-94.
10. Uldrick TS, Yarchoan RY. Hematology and Oncology in Patients with Human Immunodeficiency Virus Infection. In: Goldman L, Schafer AI (Eds). Goldman 's Cecil Medicine 25th Ed. Philadelphia, PA: Elsevier Sanders; 2015:2322-8.
11. Papanastasopoulos P, Bower M, and Uldrick TS. Primary Central Nervous System Lymphoma. In: Hentrich and Barta (Eds). HIV-Associated Hemcuologic Malignancies. New York, NY: Springer; 2016: 95-105.

C. Other Publications

1. Uldrick TS, Whitby D. Update on KSHV-Epidemiology, Kaposi Sarcoma Pathogenesis, and Treatment of Kaposi Sarcoma. *Cancer Lett.* 2011 Jun 18;305(2):150-62. PMID 21377267. [invited review]
2. Uldrick TS, Polizzotto MN, and Yarchoan R. Recent Advances in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease. *Curr Opin Oncol.* 2012 Sep;24(5):495-505. PMID 22729151. [invited review]
3. Polizzotto MN, Uldrick TS and Yarchoan Y. Case 29-2013: An HIV-positive man with dyspnea and skin lesions. Comment on: Case Records of the Massachusetts General Hospital. A 32 year-old African man with dyspnea and skin lesions. *N Engl. J Med.* 2014 Jan 87-8, 2014. PMID 24382082. [correspondence]
4. Bhutani M, Polizzotto MN, Uldrick TS and Yarchoan R. KSHV-associated Malignancies: Epidemiology, Pathogenesis, and Advances in Treatment. *Semin Oncol.* 2015 Apr;42(2):223-246. PMID 25843728. [invited review]
5. Uldrick TSS. HAART and lungs: Do HIV protease inhibitors impact cancer risk? Comment on: Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients. A nested case-control study. *AIDS.* 2015 Jun 1;29(9):1111-2. PMID 26125143. [editorial]
6. Goncalves PH, Ziegelbauer J, Uldrick TS, and Yarchoan R. Kaposi Sarcoma Herpesvirus-Associated Cancers and Related Diseases. *Curr Opin HIVAIDS.* 2017 Jan;12(1):47-56. PMID 27662501. [invited review]
7. Goncalves PH, Montezuma-Rusca JM, Yarchoan R, and Uldrick TS. Cancer Prevention in HIV-infected Populations. *Semin Oncol.* 2016 Feb 16;43(1):173-88. PMID 26970136. [invited review]
8. Uldrick TS. iNKT cell defects in HHV-8 associated MCI. *Blood.* 2017 Feb 16;129(7):806-7. PMID 28209751. [editorial]
9. Gongalves P, Uldrick TS and Yarchoan R. HIV-associated Kaposi sarcoma and related diseases. *AIDS.* 2017, Sept;31(14):1903-16. PMID 28609402. [invited review]
10. Polizzotto MN, Uldrick TS, Hu D, and Yarchoan R. Corrigendum: Clinical Manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. *Front Microbiol.* 2017 Aug 21;8:1572. PMID 28845155. [corrigendum]
11. Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. *Hematol Oncol Clin N Am.* 2018 Feb;32(1):75-88. PMID 29157621. [invited review]
12. Yarchoan R and Uldrick TS. HIV-Associated Malignancies and Related Diseases. *N Engl JMed.* 2018 Mar 15;378(11):1029-1041. PMID: 29539283. [invited review]
13. Reply to Janakiram et al. *J Clin Oncol.* 2018 April 1048-1049. PMID 29381436. [correspondence]

14. Yarchoan R and Uldrick TS. Comment on HIV-Associated Cancers and Related Diseases. *N Engl J Med*. 2018 May 31 378(22):2145. PMID 29539283. [correspondence]
15. Little RF and Uldrick TS. Are There Clues to Oral KSHV Shedding and Kaposi Sarcoma Oncogenesis in the Oral Microbiome. *J Infect Dis*. 2019 May 17. PMID 31111901. [Epub ahead of print]. [Editorial]

I). Manuscripts Submitted

1. Fajgenbaum DC, Shilling D, Partridge HL, Pierson SK, Singh A, Langan RA, Ruth JR, Nabel CS, Stone K, Chaturvedi V, Okumura M, Schwarzer A, Jose FF, Hamerschlak N, Wertheim GB, Cohen AD, Krymskaya V, Rubenstein A, Kambayashi T, Jordan MB, van Rhee F, and Uldrick TS. P13K/Akt/mTOR is a Novel Therapeutic Target in IL-6blockade Refractory iMCD. November 2018. [original work]

E. Select Abstracts

1. Uldrick T, Crew K, Tiersten A, Braffman L, Blozie K, and Hershman D. Phase II evaluation of liposomal doxorubicin combined with docetaxel in patients with metastatic breast cancer. 2005 American Society of Clinical Oncology Annual Meeting Proceedings Vol 23, No. IOS, Part I Abstract 907. June I Supplement, 2005.
2. Uldrick T, Hesdorffer M, Rasiej MJ, Austin JH, and Taub RN. ¹⁸FDG-PET in the management of malignant peritoneal mesothelioma: A retrospective review of 145 scans in 37 patients. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part 1, vol 25, No. 18S, Abstract 20519. June 20 Supplement, 2007.
3. Uldrick-TS, Mosam A, Shaik F, Friedland G, Scadden D, Jordaan JP, Aboobaker J, Coovadia HM. Prognosis of Patients with AIDS-Associated Kaposi's Sarcoma Receiving Antiretrovirals Therapy +/- Chemotherapy in KwaZulu-Natal, South Africa: An Analysis Of 1 -yr Survival Data from NCT00380770. I International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies: Basic, Epidemiologic, and Clinical Research. October 6-7, 2008.
4. Uldrick T, O'Mahony D, Aleman K, Wyvill K, Whitby D, Bernstein W, Pittaluga S, Steinberg S, Little R, and Yarchoan R. High-dose Zidovudine + Valganciclovir in the Treatment of Kaposi's Sarcoma-associated Herpesvirus-associated Multicentric Castleman's Disease: A Targeted Therapy Using Antiviral Drugs that Are Activated to Toxic Moieties by Kaposi's Sarcoma-associated Herpesvirus Lytic Genes. 16th Conference on Retroviruses and Opportunistic Infections, Abstract 864. February 8-11, 2009.
5. Uldrick T, O'Mahony D, Aleman K, wyvill KM, Whitby D, Bernstein W, Pittaluga S, Steinberg SM, Little RF, and Yarchoan R. High Dose Zidovudine plus Valganciclovir in the Treatment of Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Associated Multicentric Castleman's Disease (MCD): A Pilot Study of KSHV Targeted Anti-Tumor Therapy. Kaposi 's Sarcoma Associated Herpesvirus and Related Agents 12th International Workshop, Oral Presentation September 2009.

6. Uldrick T, Polizzotto MN, O'Mahony D, Aleman K, Wyvill K, Steinberg S, Pittaluga S, Marshall V, Whitby D, Little RF, and Yarchoan R. Clinical, Biochemical, and Radiographic Responses to Rituximab Combined with Liposomal Doxorubicin (R-Dox) in HIV-Infected Patients with Severe Kaposi Sarcoma-associated Herpes Virus (KSHV)-associated Multicentric Castleman's Disease. 51^M American Society of Hematology Annual Meeting, Abstract 1651, December 5, 2009.
7. Uldrick T, Wyvill K, Kumar P, Bernstein W, O'Mahony D, Polizzotto M, Aleman K, Steinberg S, Pittaluga S, Little R, and Yarchoan R. A Phase II Study Targeting Vascular Endothelial Growth Factor with the Humanized Monoclonal Antibody Bevacizumab in the Treatment of Patients with HIV-Associated Kaposi Sarcoma. 17th Conference on Retroviruses and Opportunistic Infections, Oral Presentation. February 17, 2010.
8. Uldrick T, Polizzotto M, O'Mahony D, Aleman K, Wyvill K, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Tosato G, Little RF, and Yarchoan R. Rituximab Combined with Liposomal Doxorubicin (R-Dox) in HIV-Infected Patients with Severe Kaposi Sarcoma-associated Herpes Virus (KSHV)-associated Multicentric Castleman Disease (MCD). 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies: Basic, Epidemiologic, and Clinical Research. Oral Presentation 08. April 26, 2010.
9. Matushansky I, Coakley KE, Uldrick TS, Taub RN. A Phase I Dose-escalation Study of Azacitidine in Combination with Temozolomide in Patients with Soft Tissue Sarcomas. American Society of Clinical Oncology 2011 Annual Meeting Abstract 10073. June 3-7, 2011.
10. Uldrick TS, Polizzotto MN, Wyvill K, Aleman K, Marshall V, Little RF, Filie A, Raffeld M, Steinberg SM, Pittaluga S, Whitby D, and Yarchoan R. Kaposi sarcoma herpesvirus (KSHV)-associated lymphomas are associated with elevated serum IL-10, IL-6, IL-17 and circulating KSHV: evidence for cytokine dysregulation in pathogenesis and symptomatology. 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies: Basic, Epidemiologic, and Clinical Research. Abstract 43. Nov. 7-8, 2011.
11. Uldrick TS, Pipkin S, Scheer S, Hessol NA. Risk factors for death and temporal trends in overall survival in patients with AIDS-associated primary central nervous system lymphoma (AIDS-PCNSL). 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies: Basic, Epidemiologic, and Clinical Research. Oral Presentation 18. November 8, 2011.
12. Uldrick TS Pipkin S, Scheer S, Hessol NA. Risk factors for death and temporal trends in overall survival in patients with AIDS-associated primary central nervous system lymphoma (AIDS-PCNSL). 19th Conference on Retroviruses and Opportunistic Infections. Abstract R-127. March 5-8, 2012.
13. Uldrick TS, Aleman K, Polizzotto MN, Wyvill KM, Steinberg SM, Raffeld M, Pittaluga S, Stetler-Stevenson M, Little RF, and Yarchoan R. AIDS-associated Primary Central Nervous System Lymphoma (AIDS-PCNSL) Treated with HAART and Radiation-sparing Therapy: The NCI HIV and AIDS Malignancy Branch Experience,

2004-2011. 19th Conference on Retroviruses and Opportunistic Infections. Abstract R-129, March 58, 2012.

14. Uldrick TS Aleman K, Polizzotto MN, wyvill KM, Steinberg S, Raffeld M, Pittaluga S, Stetler-Stevenson M, Little RF, and Yarchoan R. Treatment of Epstein Barr virus associated primary central nervous system lymphoma in patients with AIDS using immunochemotherapy: The National Cancer Institute HIV and AIDS Malignancy Branch experience, 2004-2012. International Congress on Oncogenic Herpesviruses and Associated Diseases. Abstract 1.10. August 2, 2012.
15. Uldrick TS, Polizzotto MN, Filie A, Aleman K, Wyvill KM, Little RE, Steinberg SM, ES, Whitby D, Pittaluga S, and Yarchoan R. Clinical, Immunologic, and Virologic Findings in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Lymphomas Suggest KSHV-Associated Inflammatory Syndromes Contribute to Symptoms and Disease Pathogenesis. 54th American Society of Hematology Annual Meeting, Abstract 2708. December 9, 2012.
16. Anderson E, Spindler J, Boltz V, Shao W, Uldrick T, Rehm C, Kearney M, Mellors J, Coffin J, Maldarelli F. Persistent Low Level Viremia During Antiretroviral Therapy: Implications for Viral Reservoirs. 20th Conference on Retroviruses and Opportunistic Infections. Mar 3-6, 2013.
17. Uldrick JS, wyvill KM, Peer C, Polizzotto MN, O'Mahony D, Bernstein W, Aleman K, Steinberg SM, Venzon D, Pittaluga S, Little RF, Figg WD, Yarchoan R. Phase I and pharmacokinetic study of sorafenib in Kaposi sarcoma. American Society of Clinical Oncology 2013 Annual Meeting, Abstract 10588. Jun 1, 2013.
18. Uldrick TS Polizzotto MN, Pittaluga S, Filie A, Aleman K, Wyvill KM, Steinberg SM, Little RF, Whitby D, Jaffe ES, and Yarchoan R. KSHV-associated inflammatory cytokine syndromes contribute to symptoms and disease pathogenesis in KSHV associated lymphomas. 16th International Workshop on Kaposi 's Sarcoma Herpesvirus (KSHV) and Related Agents. Oral Presentation, June 30, 2013.
19. Chen Y* , Uldrick TS*, Polizzotto MN, Wyvill KM, Aleman K, Steinberg SM, Pittaluga S, Marshall V, Little RF, Whitby D, and Yarchoan R. Pleural effusions in patients with Kaposi sarcoma are associated with high levels of intracavitary IL-6 and IL- 10 suggesting that intracavitary inflammation contributes to disease pathophysiology. 14th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies. Bethesda, MD. November 13, 2013.
20. Rous C, Weaver L, Salem S, Yuan CM, Uldrick TS Stetler-Stevenson M. Optimizing flow-cytometric detection of Kaposi sarcoma herpesvirus-associated lymphoproliferative disease. NIH Summer Research Program Poster Day, Bethesda, MD. August 7, 2014.
21. Uldrick TS Bhutani M, Polizzotto MN, Aleman KO, wyvill KM, Goncalves PH, Pittaluga S, Filie A, Marshall V, Rupert AW, Tosato G, Whitby D, Little RF, Steinberg SM and Yarchoan R. Inflammatory Cytokines, Hyperferritinemia, and IgE are Prognostic in Patients with KSHV-Associated Lymphomas Treated with Curative Intent Chemotherapy. 56th American Society of Hematology Annual Meeting. Abstract 3001, December 7, 2014.

22. Polizzotto MN, sereti 1, Uldrick TS, wyvill KM, Jensen SM, Singh A, Kovacs SB, Aleman KO, Marshall V, Whitby D, Maldarelli F, Steinberg SM, Zeldis JB, and Yarchoan R. Pomalidomide Induces Expansion of Activated and Central Memory CD4+ and CD8+ T Cells in Vivo in Patients with and without HIV Infection. 56th American Society of Hematology Annual Meeting, Abstract 4128. December 8, 2014.
23. Waters SA, Shao W, Dunleavy K, Shovlin M, Polizzotto MN, Uldrick TS, Yarchoan R, Wilson W, and Maldarelli F. Effects of Antineoplastic Chemotherapy on Dynamics of HIV Population Genetics In Vivo. Conference on Retroviruses and Opportunistic Infections 2015. Abstract 399, February 22-25, 2015.
24. Uldrick TS Polizzotto MN, Goncalves P, Aleman K, Wyvill KM, Steinberg SM, Whitby D, Little RF, Yarchoan R. Abstract 201. Outcomes in Kaposi Sarcoma Herpesvirus-associated Multicentric Castlemann Disease Patients Treated with Rituximab and Liposomal Doxorubicin (R-Dox). Poster 201. 14th International Conference on Malignant Lymphoma. In: Hematol Oncol June 2015; 13(S 1): 204.
25. Uldrick TS Polizzotto MN, Bhutani M, Aleman K, Wyvill KM, Gongalves PH, Pittaluga S, Filie A, Little RE, Steinberg SM, Marshall V, Whitby D, and Yarchoan R. KSHV-associated Inflammatory Biomarkers are Prognostic in Patients with Primary Effusion Lymphoma. 18th International Workshop on KSHV and Related Agents. Oral Presentanon, July 2, 2015.
26. Gongalves PH, Uldrick TS, Aleman K, Polizzotto MN, Wyvill MN, Steinberg SM, Pittaluga S, Stetler-Stevenson M, Yuan C, Little R, and Yarchoan R. Radiation-Sparing Treatment of Acquired Immune Deficiency Syndrome (AIDS)- Related Primary Central Nervous System Lymphoma (PCNSL) with Highly Active Antiretroviral Therapy (HAART), Rituximab, and High Dose Methotrexate with Leucovorin Rescue. 15th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies. Oral Presentation 19. Bethesda, MD. October 27, 2015.
27. Labo N, Marshall V, Cornejo Castro EM, Vengurlekar P, Wyvill KM, Aleman K, Polizzotto MN, Uldrick TS, Keele BF, Yarchoan R and Whitby D. Shotgun Next Generation Sequencing of Whole g-Herpesvirus Genomes from Clinical Samples. Abstract 92. 15th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies. October 26-27, 2015.
28. Bozzi G, Watters S, Simonetti F, Anderson E, Gorelick R, Shao W, Bell J, Rehm C, Dewar R, Yarchoan R, Uldrick T, and Maldarelli F. No Evidence of Ongoing Replication in Tissue Compartments During Combination Antiretroviral Therapy. 21st International AIDS Conference. Late Breaker Oral Session, July 22, 2016.
29. Marshall V, Cornejo Castro E, Labo N, Immonen T, Vengurlekar P, Wyvill K, Aleman K, Lurain K, Polizzotto M, Keele B, Yarchoan R, Uldrick T Whitby D. Whole Gene Sequence Analysis of KSHV from Clinical Samples. 20th International Workshop on Kaposi 's Sarcoma Herpes Virus (KSHV) and Related Agents, Oral Presentation. July 25, 2017.

30. Lurain K, Labo N, Miley W, Miley W, Gongalves PH, Marshal V, Yarchoan R, Whitby D, and Uldrick TS. Proteomic analysis of host response to KSHV in HIV-infected patients with KSHV-associated diseases. 16th International Conference on Malignancies in HIV/AIDS. Bethesda, MD. October 20-21, 2017.
31. Lurain K, Polizzotto M, Goncalves PH, Filie AC, Steinberg SM, Marshall V, Miley W, Little R, Whitby D, JafTe ES, Pittaluga S, Yarchoan R, and Uldrick TS. Tumor EpsteinBarr virus status is prognostic in primary effusion lymphoma. 16th International Conference on Malignancies in HIV/AIDS. Oral Presentation. Bethesda, MD. October 20-21, 2017.
32. Goncalves PH, Labo N, Ramaswami R, Jack D, Marshall V, Lurain K, Yarchoan R, Whitby D and Uldrick TS. Kaposi Sarcoma Herpesvirus shedding in saliva of patients with KSHV-associated malignancies. 16th International Conference on Malignancies in HIV/AIDS. Bethesda MD. October 20-21, 2017.
33. Fajgenbaum DC, Shilling D, Partridge HL, Pierson SK, Ruth JR, Nabel CS, Jordan MB, Cochen AD, Krymskaya V, Rubenstein AH, van Rhee F, Uldrick TS. Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach. 59th American Society of Hematology Annual Meeting. Atlanta, GA. December 7, 2017.
34. Fajgenbaum DC, Pierson SK, Shilling D, Gardner C, Liu AY, Ziglar J, Bernstein S, Mann S, Zuckerberg J, Lukac M, Jayanthan RK, Guilfoyle M, Tendler C., Ruth J, Uldrick TS, van Rhee F. Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease. 59th American Society of Hematology Annual Meeting Atlanta, GA. December 7, 2017.
35. Uldrick TS, Gongalves PH, Fling S, Emu B, Ernstoff MS, Kaiser J, Lindsley M, Lundgren L, Lurain K, Gorelick R, Maldarelli F, Sharon E, Yarchoan R, and Cheever MA. Interim Safety Analysis of CITN-12: Pembrolizumab in Patients with HIV and Cancer. Conference on Retroviruses and Opportunistic Infections 2015. Late Breaking Abstract 656. Boston, MA. March 5, 2018.
36. Lurain K, Polizzotto MN, Gongalves PH, Ramaswami R, Marshall V, Miley W, Steinberg SM, Little RF, Wilson W, Filie AC, Pittaluga S, Jaffe ES, Whitby D, Yarchoan R, and Uldrick TS. Tumor Epstein Barr Virus Status is Prognostic in Primary Effusion Lymphoma. 2018 International Conference on EBV and KSHV. Oral Presentation. Madison, WI. July 30, 2018.
37. Roshan R, Lurain K, Labo N, Ramaswami R, Uldrick T, Gongalves P, Widell A, Marshall V, Yarchoan R, and Whitby D. Interferon- γ Responses in Peripheral Blood Mononuclear Lymphocytes of Patients with KSHV-associated Diseases Treated with Pomalidomide and Liposomal Doxorubicin. 2018 International Conference on EBV and KSHV, Oral Presentation. Madison, WI. July 31, 2018.
38. Lurain K, Labo N, Miley W, Ramaswami R, Uldrick TS, Goncalves PH, Polizzotto MN, Marshall V, Widell A, Whitby D, Yarchoan R. Kaposi Sarcoma Herpesvirus Humoral Response in Kaposi Sarcoma Patients with and without HIV Treated with Pomalidomide. 2018 International Conference on EBV and KSHV. Madison, WI. July 29-30, 2018.

39. Ramaswami R, Uldrick T, Polizzotto MN, Gongalves P, Lurain K, Widell A, Aleman K, Wyvill K, Steinberg S, Figg WD, Tosato G, Whitby D, and Yarchoan R. A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab Followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. 2018 International Conference on EBV and KSHV, Madison, WI. July 29-30, 2018.
40. Lurain K, Polizzotto MN, Gongalves PH, Ramaswami R, Aleman K, Marshall V, Miley W, Steinberg SM, Little RE, Wilson W, Filie AC, Pittaluga S, Jaffe ES, Whitby D, Yarchoan R, and Uldrick TS. Viral and Immunologic Prognostic Factors in Primary Effusion Lymphoma, American Society of Hematology Meeting on Lymphoma Biology. Chantilly, VA. August 2-5, 2018.
41. Lurain K, Uldrick TS, Gongalves PH, Ramaswami R, Aleman K, Polizzotto MN, Widell A, Steinberg SM, Jaffe ES, Pittaluga S, Stetler-Stevenson, Yuan C, Little RF and Yarchoan R. Radiation Sparing Treatment of HIV-related Primary Central Nervous System Lymphoma with Antiretroviral Therapy, Rituximab and High-Dose Methotrexate. American Society of Hematology Meeting on Lymphoma Biology. Chantilly, VA. August 2-5, 2018.
42. Ramaswami R, Lurain K, Widell A, Polizzotto MN, Gongalves PH, Lindsley M, Steinberg SM, Whitby D, Uldrick TS, Yarchoan R. Pilot Study of tocilizumab in patients with HIV and symptomatic Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease. 60th Annual American Society of Hematology Meeting. San Diego, CA. Dec. 2018.
43. Okello CD, D'dungu H. , Omoding A, Towler AMH, Pitorak H, Maggard K, Ewart S, Phipps WT, Uldrick TS Warren EH, Orem J. Capacity building for hematologic malignancies in Uganda: a comprehensive research, training, and care program through the Uganda Cancer Institute-Fred Hutchinson Cancer Research Center Collaboration. 60th Annual American Society of Hematology Meeting. San Diego, CA. Dec. 2018.
44. Ramaswami R, Lurain K, Goncalves PH, Polizzotto M, Widell A, Lindsley M, Little RF, Uldrick TS, Yarchoan R. Long-term outcomes of 58 patients with HIV and KSHV+ multicentric Castleman disease. Abstract 17. Conference on Retroviruses and Opportunistic Infections. Oral Presentation. Seattle, WA. March 5, 2019.
45. Uldrick TS, Fling S, Adams SV, Solomon A, Goncalves PH, Chomont N, Gorelick R, Lifson JD, Yarchoan R, Cheever MA, Maldarelli M, Deeks SG, Lewin SR. Pembrolizumab induces HIV latency reversal in HIV+ individuals on ART with Cancer. Abstract 27. Conference on Retroviruses and Opportunistic Infections. Oral Presentation. Seattle, WA. March 5, 2019.

17. Other

A. Patents

Yarchoan R, Zeldis JB, Polizzotto MN, Davis DA, sereti 1, Uldrick TS, Whitby D, and Khetani V. Patent No. US 10,001,483 B2. Methods for the treatment of Kaposi's sarcoma or

KSHV-induced lymphoma using immunomodulatory compounds and uses of biomarkers.
June 19, 2018

B. Invited Peer Review

AIDS

American Society of Clinical Oncology - Self-Evaluation Program Y^d Edition Archives
of Dermatologic Research

Blood

Blood Advances

BMC Hematology

British Journal of Cancer

Clinical and Vaccine Immunology

Clinical Infectious Diseases

Current HIV Research

Deutsche Forschungsgemeinschaft (German Research Foundation)

Expert Opinion on Orphan Drugs

Frontiers in Microbiology

German Research Foundat

Immunotherapy — Future Medicine

Haematologica

Health and Human Resources Panel on Antiretroviral Guidelines for Adults and
Adolescents

Infectious Agents and Cancer

International Journal of Cancer

Journal of Acquired Immune Deficiency Syndromes

Journal of Clinical Imaging Science

Journal of Clinical Investigation

Journal of Clinical Oncology

Journal of Global Oncology

Journal of Infectious Diseases Lancet

New England Journal of Medicine

The Medical Letter

Plos One

Postgraduate Committee, Stellenbosch University, South Africa Viruses